18F-DCFPyL PSMA PET/CT 预测阿比特龙或恩扎卢胺治疗去势抵抗性前列腺癌的疗效
结果显示治疗2-4月后的PSMA PET摄取变化模式与至治疗更换时间和总生存相关,新发病灶或基线病灶摄取强度增加提示预后不良。
要点
- 治疗2-4月后PSMA PET出现混合但以摄取增加为主的模式,与更短的TTTC和OS相关。
- 高DPSM或高DASM患者的TTTC和OS均显著短于低值患者。
- 新发病灶或基线病灶摄取强度增加提示预后不良。
核心结论
- 起始阿比特龙或恩扎卢胺后2-4月的PSMA靶向PET表现与至治疗更换时间和总生存相关。
- 新发病灶或基线病灶放射性摄取强度增加为不良预后征象,提示更短的TTTC和OS。
研究设计与样本
- 前瞻性、单臂、两中心探索性临床试验,纳入起始阿比特龙或恩扎卢胺的转移性去势抵抗性前列腺癌患者。
- 每例患者在基线和治疗开始后2-4月行18F-DCFPyL PET/CT,随访至入组后48月。
- 中央评阅评估基线和随访PET,记录所有疾病部位SUVmax变化并分类变化模式,衍生DPSM和DASM两个参数。
- 采用Kaplan-Meier曲线估计至治疗更换时间和总生存。
主要发现
- 中位TTTC为9.6月(95%CI 6.9-14.2),中位OS为28.6月(95%CI 18.3-NA)。
- 混合但以放射性摄取增加为主的模式患者TTTC和OS更短。
- 低DPSM患者中位TTTC为12.2月(95%CI 11.3-NA)、中位OS为37.2月(95%CI 28.9-NA);高DPSM患者中位TTTC为6.5月(95%CI 4.6-NA,P=0.0001)、中位OS为17.8月(95%CI 13.9-NA,P=0.02)。
- 低DASM患者中位TTTC为12.2月(95%CI 11.3-NA)、中位OS为NA(95%CI 37.2月-NA);高DASM患者中位TTTC为6.9月(95%CI 6.1-NA,P=0.003)、中位OS为17.8月(95%CI 13.9-NA,P=0.002)。
关键数值与推荐
- DPSM定义为所有病灶SUVmax的δ百分比,DASM定义为所有病灶SUVmax的δ绝对值。
- 随访PET在治疗开始后2-4月内完成,随访至入组后48月。
临床怎么用
- 对起始阿比特龙或恩扎卢胺的转移性去势抵抗性前列腺癌患者,可考虑在治疗2-4月行PSMA靶向PET/CT评估摄取变化。
- 若出现新发病灶或基线病灶摄取强度增加,提示TTTC和OS较短,需加强随访或考虑调整治疗策略。
局限性
- 部分生存分析置信区间上限为NA,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET with small molecules targeting prostate-specific membrane antigen (PSMA) is being adopted as a clinical standard for prostate cancer imaging. In this study, we evaluated changes in uptake on PSMA-targeted PET in men starting abiraterone or enzalutamide. Methods: This prospective, single-arm, 2-center, exploratory clinical trial enrolled men with metastatic castration-resistant prostate cancer initiating abiraterone or enzalutamide. Each patient was imaged with 18F-DCFPyL at baseline and within 2-4 mo after starting therapy. Patients were followed for up to 48 mo from enrollment. A central review evaluated baseline and follow-up PET scans, recording change in SUVmax at all disease sites and classifying the pattern of change. Two parameters were derived: the δ-percent SUVmax (DPSM) of all lesions and the δ-absolute SUVmax (DASM) of all lesions. Kaplan-Meier curves were used to estimate time to therapy change (TTTC) and overall survival (OS). Results: Sixteen evaluable patients were accrued to the study. Median TTTC was 9.6 mo (95% CI, 6.9-14.2), and median OS was 28.6 mo (95% CI, 18.3-not available [NA]). Patients with a mixed-but-predominantly-increased pattern of radiotracer uptake had a shorter TTTC and OS. Men with a low DPSM had a median TTTC of 12.2 mo (95% CI, 11.3-NA) and a median OS of 37.2 mo (95% CI, 28.9-NA), whereas those with a high DPSM had a median TTTC of 6.5 mo (95% CI, 4.6-NA, P = 0.0001) and a median OS of 17.8 mo (95% CI, 13.9-NA, P = 0.02). Men with a low DASM had a median TTTC of 12.2 mo (95% CI, 11.3-NA) and a median OS of NA (95% CI, 37.2 mo-NA), whereas those with a high DASM had a median TTTC of 6.9 mo (95% CI, 6.1-NA, P = 0.003) and a median OS of 17.8 mo (95% CI, 13.9-NA, P = 0.002). Conclusion: Findings on PSMA-targeted PET 2-4 mo after initiation of abiraterone or enzalutamide are associated with TTTC and OS. Development of new lesions or increasing intensity of radiotracer uptake at sites of baseline disease are poor prognostic findings suggesting shorter TTTC and OS.
引用
- Zukotynski KA, Emmenegger U, Hotte S, et al. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. J Nucl Med. 2021. PMID: 33608426. doi:10.2967/jnumed.120.259069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。